Clinical trial
Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine
NCT04069897 is registered in ClinicalTrials.gov with St. Olavs Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine
- Lead sponsor
- St. Olavs Hospital
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 1, 2019
- Completion date
- June 13, 2026
- Enrollment
- 170 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.